Slide 1: Eden Research plc 2022 Prelims
Eden Research plc 2022 Prelims May 2023
Slide 2: Eden Research plc is an AIM-quoted company
Eden Research plc is an AIM-quoted company focused on sustainable biopesticides and plastic-free encapsulation technology for use in the global crop protection, animal health and consumer products industries.
Slide 3: About us / Key statistics
About us Key statistics Eden is the only UK quoted (AIM: EDEN) company focused on biopesticides for sustainable agriculture 19 • Intellectual property and expertise in plant-derived Countries have granted Consumer product authorisation sustainable chemistry products and delivery technologies • Prove
Slide 4: Industry applications
Industry applications We work globally through multi-national and local partnerships to develop and launch solutions for challenges facing three key industries. Consumer products Crop protection Animal health Head-lice treatment Foliar disease & Shampoos/Conditioners Deodorants insect control Skin d
Slide 5: The Drive Towards Sustainable Agriculture
The Drive Towards Sustainable Agriculture Farming practices which Embracing farming maintain yields while increasing practices that mimic natural benefits for the environment ecological processes Eden formulations are A reflection of society’s A win-win for farmers and well suited for a wide increas
Slide 6: Significant Market Potential
Significant Market Potential $11bn Crop protection products formulated with Sustaine® and Eden’s active ingredients can help address many of these issues: The global biopesticides market is projected to be worth more than $11 billion by 2027 Consumer concerns 15% per annum over food safety The biope
Slide 7: 2022 Financial Highlights
2022 Financial Highlights 2022 2021 audited audited Notes: Revenue £1.8m £1.2m § Revenue for the year increased by approximately 50% to £1.8m, £0.1m, or 6%, ahead of market expectations Product sales revenue £1.6m £1.1m of £1.7m (FY2021: £1.2m) Other revenue £0.2m £0.1m § Product sales increased by
Slide 8: Product sales growth
Product sales growth Eden product sales 2020 - 2022 Sales of Mevalone made by our distribution partners in the same period Eden product sales (€) reflect a positive overall trend driven by 2,000,000 the addition of new territories (e.g. Australia) 1,800,000 and label expansions (e.g. Spain). 1,600,0
Slide 9: 2022 Non-Financial Highlights
2022 Non-Financial Highlights Revenue £1.8m £1.2m § US EPA national approval received for Mevalone®, Cedroz™ and three active ingredients in ProductSeptember sales revenue 2022 £1.7m £1.1m Other revenue £0.1m £0.1m § Initial US state approvals received before year-end with additional approvals expec
Slide 10: Innovation Capacity
Innovation Capacity Development of Laboratories are Progress is being in-house R&D – now GLP-ready and made on the potential reduces dependency operating to this benefits of the on 3rd parties, standard adding second-generation CROs, etc. In-house capabilities credibility and Costs partially offset
Slide 11: Strategy and Investment Case
Strategy and Investment Case
Slide 12: Our Strategy
Our Strategy Research, Business line Commercial Strengthening and development diversification growth growing the team and operations • Pursuit of opportunities in seed • Supply chain optimisation • Regulatory clearance in new • Added capacity in R&D, including treatments • Expansion of in-house scre
Slide 13: Commercial Footprint
Commercial Footprint Our presence in Europe grew in 2021-22 through new authorisations for both Cedroz™ and Mevalone®, and we anticipate further approvals in Europe and further abroad in 2023. Our US EPA approval for the sale of Mevalone® and CedrozTM was granted in September 2022. Commercial Approv
Slide 14: Mevalone Regulatory Progress 2019 - 2021
Mevalone® Regulatory Progress 2019 - 2021 Since 2019 31 5x Increase in disease targets 12 13 10 10 8 5x 2 6 4 Increase in crop authorisations 2019 2020 2021 30% No. countries authorised Increase in country No. of disease targets authorisations No. of Crops
Slide 15: Regulatory position
Regulatory position EFSA (EU) Organic (EU) • Application for the renewal of Eden’s three • All three of Eden’s active ingredients have active ingredients (eugenol, geraniol and thymol) been approved as inputs for organic has been submitted to EFSA for its review. agriculture in the EU. • The renewed
Slide 16: Our product focus
Our product Our focus is on developing products based on sustainable chemistries to protect crops from pests focus and disease, with equal or better performance when compared with conventional pesticides. FUNGICIDES NEMATICIDES INSECTICIDES SEED TREATMENTS Botrytis, powdery Root knot Mites and Multi
Slide 17: Product Characteristics
Product Characteristics Enabling sustained Tackling Solvent-free, stable Protecting plants Polymer-free ‘Residue Low or no delivery, increasing resistance formulations with from potentially formulation free’ pre-harvest intervals residual efficacy and build-up high loadings of damaging chemicals tec
Slide 18: Positive Outlook for Organic Growth
Positive Outlook for Organic Growth How organic growth will be achieved The team at Eden now has the necessary capabilities to formulate, develop, test (up to pot plant level) and register products that it has created. Label extensions and country approvals of Mevalone and Cedroz continue to increas
Slide 19: Mevalone Biofungicide
Mevalone® Biofungicide Background Current status Mevalone is a foliar biofungicide which was Approved in Southern EU on a wide range of targets and crops developed initially to target botrytis on grapes. Approved in Kenya and Australia Since its launch in the EU in 2016, the label for Approval in th
Slide 20: Cedroz Bio-nematicide
Cedroz™ Bio-nematicide Background Current status Cedroz is a bio-nematicide targeting Approved in Southern and Central EU on a wide range root-knot nematodes in high value crops. of high-value crops A development and commercialisation Approval in the US received in September 2022 agreement was signe
Slide 21: Downy mildew: Filling a gap in the market
Downy mildew Filling a gap in the market Background Current status Due to the recent restriction of a number Second year regulatory field trials are complete of key downy mildew products, there is a with good results received. strong need for replacement products. There are currently three potential
Slide 22: Significant additional growth opportunities
Significant additional growth opportunities Cannabis Other Eden has been approached by a new potential partner Evaluations in additional to see if Mevalone, or any other Eden formulation, areas of significant commercial would be suitable to target the cannabis market in the potential include black U
Slide 23: Organic Growth: New Products
Organic Growth: New Products
Slide 24: Seed Treatments
Seed Treatments Key information What are Seed Treatments? Physical, biological or chemical agents applied SEED SEED SEED to seeds to provide protection and help improve overall crop performance DRESSING COATING PELLETING Multiple functions: supporting greater uniformity of seed germination, plant he
Slide 25: Seed Treatments – Corteva
Seed Treatments – Corteva On the path to commercialisation Background Current status Two incumbent ingredients used in Semi-field studies have shown good efficacy Corteva’s seed treatment products have been, or will shortly be, banned in key Field trials, undertaken by both parties, showed efficacy
Slide 26: Insecticide
Insecticide Significant opportunities for effective, new products Background Current status Due to a ban on numerous insecticides, Initial data received from the field trials undertaken in 2022 shows such as neonicotinoids, there is a large good efficacy, consistent with that in 2021 opportunity for
Slide 27: Sustaine projects
Sustaine® projects Addressing the rising microplastics issue Background Current status In addition to using microencapsulation Field trials underway with multiple industry partners. system, Sustaine, in our in-house developed products, such as Mevalone and Cedroz, Decisions regarding future evaluati
Slide 28: Thank you
THE NATURAL SOLUTION Thank you
Slide 29: A Strong Team
A Strong Team Lykele van der Robin Cridland Sean Smith Alex Abrey Broek Non-Executive CEO CFO Chairman Director Sean Smith CEO Richard Horsman Non-Executive Director Alex Abrey CFO Laboratories and Commercial Head of Product Director of Head of R&D Facilities Manager Director Management Regulatory A